Is HTBX a good value stock to buy now?
HTBX has a Quality Grade of D, ranking ahead of 6.36% of graded US stocks. HTBX's asset turnover comes in at 0.018 -- ranking 373rd of 680 Pharmaceutical Products stocks. ALNY, TXMD, and ENTA are the stocks whose asset turnover ratios are most correlated with HTBX. The table below shows HTBX's key quality metrics over time.
Will Heat Biologics (HTBX) stock split on the NASDAQ?
On Oct. 5 at 7pm (ET), Louis Navellier & Eric Fry will reveal one of the best-kept secrets in investing: How to turn small stock moves into big gains… and large moves into massive winners! Sign Up Here, FREE! Heat Biologics (NASDAQ: HTBX) has announced details for a reverse stock split in order to keep shares of HTBX stock trading on the Nasdaq.
Is HTBX a sell or buy on Robinhood?
Today HTBX ranks #10000 as sell candidate. Get a Free Stock at Robinhood Which way will HTBX go? * StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.
Is HTBX stock a buy?
The Heat Biologics stock holds a sell signal from the short-term moving average; at the same time, however, there is a buy signal from the long-term average. Since the short-term average is above the long-term average there is a general buy signal in the stock giving a positive forecast for the stock.
Who owns HTBX stock?
HTBX Institutional Ownership - Heat Biologics Inc (NASDAQ) StockLEI549300C7CB2MWG4V3I09Institutional Value (Long)$ 8,580 USD ($1000)RelatedDE:1HB1 / Heat Biologics Inc (72 owners) DE:1HB / Heat Biologics Inc (68 owners) GB:0A4E / Heat Biologics Inc (71 owners)3 more rows
What happened to Heat Biologics stock?
The clinical-stage biotech, Heat Biologics (NYSE:HTBX), announced on Tuesday that it would change its name to NightHawk Biosciences effective May 03. The name change will coincide with a change in the company's ticker symbol to “NHWK” on the same day.
Is Heat Biologics a good company?
While Heat Biologics seems to be in a fairly good position, it's still worth considering how easily it could raise more cash, even just to fuel faster growth. Companies can raise capital through either debt or equity. Commonly, a business will sell new shares in itself to raise cash and drive growth.
What is PTX 35?
PTX-35 is a novel, potential first-in-class antibody immunomodulator of TNFRSF25 (death receptor 3), a receptor that is preferentially expressed by antigen-experienced T cells and can be manipulated to expand regulatory T-cell subsets.
When is Heat Biologics' next earnings date?
Heat Biologics is scheduled to release its next quarterly earnings announcement on Tuesday, August 9th 2022. View our earnings forecast for Heat B...
Who are Heat Biologics' key executives?
Heat Biologics' management team includes the following people: Mr. Jeffrey Alan Wolf J.D. , Founder, Chairman, CEO & Pres (Age 59, Pay $1.31M) M...
Who are some of Heat Biologics' key competitors?
Some companies that are related to Heat Biologics include Verona Pharma plc (VRP.L) (VRP) , Bioventix (BVXP) , Agronomics (ANIC) , Fennec Pharm...
What other stocks do shareholders of Heat Biologics own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Heat Biologics investors own include Sorrento Therapeutics...
What is Heat Biologics' stock symbol?
Heat Biologics trades on the NASDAQ under the ticker symbol "HTBX."
Who are Heat Biologics' major shareholders?
Heat Biologics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Jane Street Group LLC (...
Which institutional investors are buying Heat Biologics stock?
HTBX stock was bought by a variety of institutional investors in the last quarter, including Jane Street Group LLC, and Group One Trading L.P..
How do I buy shares of Heat Biologics?
Shares of HTBX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBul...
How much money does Heat Biologics make?
Heat Biologics (NASDAQ:HTBX) has a market capitalization of $0.00.
Signals & Forecast
Support, Risk & Stop-loss
A buy signal was issued from a pivot bottom point on Thursday, January 27, 2022, and so far it has risen 5.14%. Further rise is indicated until a new top pivot has been found. Furthermore, there is a buy signal from the 3 month Moving Average Convergence Divergence (MACD).
Is Heat Biologics stock A Buy?
Heat Biologics finds support from accumulated volume at $2.65 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.
Insiders are very positive buying more shares than they are selling in Heat Biologics
Heat Biologics holds several negative signals and is within a very wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock.
About Heat Biologics
In the last 100 trades there were 20.91 million shares bought and 216.62 thousand shares sold. The last trade was done 54 days ago by Monahan John J who bough 32.47 thousand shares. The large amount of stocks bought compared to stocks sold indicate that the insiders believe there is a potential good upside.
Golden Star Signal
Heat Biologics, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel allogeneic off-the-shelf cellular therapeutic vaccines for a range of cancers and infectious diseases in the United States.
Top Fintech Company
This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star. This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!
Component Grades
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
HTBX POWR Grades
We have 9 different ratings for every stock to help you appreciate its future potential. You can unlock it all now.
HTBX Stock Summary
Value is the dimension where HTBX ranks best; there it ranks ahead of 60.19% of US stocks.
HTBX Valuation Summary
HTBX's price/sales ratio is 36.12; that's higher than the P/S ratio of 95.04% of US stocks.
HTBX's Quality Factors
In comparison to the median Healthcare stock, HTBX's price/sales ratio is 559.91% higher, now standing at 74.9.
Latest HTBX News From Around the Web
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
Heat Biologics (HTBX)
Below are the latest news stories about Heat Biologics Inc that investors may wish to consider to help them evaluate HTBX as an investment opportunity.
Chart for HTBX
This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.